Editorial: Effector functions of therapeutic antibodies

Therapeutic antibodies are broadly used in both oncology and autoimmune indications. Currently there are more than hundred antibodies approved by the FDA and many more are in development. Therapeutic antibodies of the human IgG1 subclass with an unmodified Fc portion are increasingly being replaced with engineered antibodies or novel antibody formats. In order to improve the therapeutic index of antibodies, the Fc portion of IgG can be protein- or glyco-engineered (1). Other IgG subclasses or antibody isotypes are also being explored. These modifications are aimed at altering the natural interactions with immune effector functions, such as Fc receptors or the complement system to ultimately improve the efficacy and safety of therapeutic antibodies.

Rights

Use and reproduction:


CC BY 4.0

Please note that individual components of the publication may be subject to other licensing or copyright conditions.

Cite

Citation style:
Could not load citation form.